Many people make it a New Year's resolution to start investing -- a laudable goal. The good news is that doing so doesn't require millions of dollars in the bank. Even with $500, a relatively modest sum, new and seasoned investors alike can get their hands on solid companies with excellent growth prospects.

In fact, let's consider two examples: Sarepta Therapeutics (NASDAQ: SRPT) and Veeva Systems (NYSE: VEEV). A single share of either of these costs well below $500, and both are worth investing in. Let's dig deeper.

Sarepta Therapeutics develops medicines for rare diseases, particularly one known as Duchenne muscular dystrophy (DMD), an inherited condition that causes progressive muscle waste. The biotech's lineup features four therapies for DMD. Its latest approved treatment, Elevidys, was the most important yet. It is a gene therapy that addresses DMD's underlying causes and serves as a one-time treatment for eligible patients.

Continue reading

Source Fool.com